25
Arrhythmias RVS Chaitanya koppala

Pharmacotherapy of Arrhythmias

Embed Size (px)

Citation preview

Page 1: Pharmacotherapy of Arrhythmias

Arrhythmias

RVS Chaitanya koppala

Page 2: Pharmacotherapy of Arrhythmias

Normal cardiac electrophysiology• Normal cardiac rhythm, sinus rhythm is characterized by contraction

of first atria and ventricles (Systole) followed by relaxation (diastole) during with the heart fill with blood before the next cardiac cycle begins• Above mention sequence is maintained by electrical activity of heart’s• Myocytes are electrically active and capable of generating action

potential.• Adjacent myocytes form the connections with the adjacent myocytes

through channels / protein channels called gap junctions

Page 3: Pharmacotherapy of Arrhythmias

Cardiac action potential• Understanding of ionic basis of the cardiac action potential is

important (?)• Inherited abnormalities of ion channels functions (channelopathies)

are an important cause of sudden cardiac death (?)• Phospholipid membrane of the cardiac myocytes is spanned by

numerous proteins = ion channels• Permeablility to specific ions= diastolic depolarization + resting

membrane potential+ pacemaker activity + action potentials

Page 4: Pharmacotherapy of Arrhythmias

• Resting membrane potential is -60 to -90 mV (more intracellular than extracellular (?) bcz of Na+/k+ - ATPase • Which pumps K+ ions into cell in exchange for Na+ ions,• Pumps K+ ions out of the cell with unaccompanied by anions resulting

in the net loss of charge and thus a negative resting/ diastolic/phase 4• Specialised myocytes form the cardiac conduction system and these

cell have pacemaker activity• Influenced by sympathetic nervous system ( Camp) and

parasympathetic nervous system by circulating catecholamines

Page 5: Pharmacotherapy of Arrhythmias
Page 6: Pharmacotherapy of Arrhythmias

RefractorinessAction potential of cardiac myocytes differs from that seen in nerve cells by the presence of a plateau phase (myocyte is inexictable and refractory)The time interval b/n the onset of the action potential and the regaining of the electrical excitability is known as the refractory period“Drugs that prolong the action potential duration (APD) prolong the refractory period”

Page 7: Pharmacotherapy of Arrhythmias

Normal cardiac conduction

Page 8: Pharmacotherapy of Arrhythmias

Normal electrocardiogram (ECG)

Page 9: Pharmacotherapy of Arrhythmias

Arrhythmia mechanismsCauses

• Abnormal impulse formation

• Abnormal impulse propagation

Page 10: Pharmacotherapy of Arrhythmias

Abnormal impulse formation Abnormal automaticity:Another term for pacemaker activityRate of firing of pacemaker is largely determined by the duration of

the phase 4 (?)PHASE 4: determined by

1. Max diastolic potential following repolarisation of preceeding AP2. Slope of the diastolic depolarization (pacemaker currents)3. Threshold potential for generation of a new action

Page 11: Pharmacotherapy of Arrhythmias
Page 12: Pharmacotherapy of Arrhythmias

Trigger activity• Describes impulse formation dependent upon after depolarization • EADs (During phase 2/3)• DADs (During Phase 4)• In both cases after depolarization may reach the threshold potential

required for generation of a new action potentialEADs DADs

Congenital and acquired long QT syndromes Reperfusion following ischaemia, heart failure, digitalis toxicity and catecholamine

polymorphic VTProlonged APD promotes reactivation of the

inward calcium currents Spontaneous release of calcium in burst by

Sarcoplasmic reticulumActivation of Na+/Ca2+ EXCHANGER

Page 13: Pharmacotherapy of Arrhythmias
Page 14: Pharmacotherapy of Arrhythmias

Abnormal impulse propagation Re-entry: many clinically arrhythmias are due to re- entry in which an activation wave front rotates continuously around a circuitPrecise set of electrophysiological conditions must be met in order for re – entry to occur1. premature beat must encounter unidirectional condition2.Central non conducting obstacle around which re entry circuit develops3. Conduction proceed slowly enough down the other limb4. Circulating wave front activation must continue to encounter electrically excitable tissue

Page 15: Pharmacotherapy of Arrhythmias
Page 16: Pharmacotherapy of Arrhythmias

Clinical problems

Patients with cardiac arrhythmia may present with a number of symptomsPalpitations Sudden drop in cardiac outputSinus tachycardia Dizziness, syncope, sudden deathReduced cardiac output Atrial tachyarrhythmias/ flutterReduced exercise capacity Atrial fibrillation BreathlessnessFatigueAnginaMyocardial infarction

Page 17: Pharmacotherapy of Arrhythmias

Arrhythmias may aggravate heart failure in two ways:

1. Haemodynamic effect of the arrhythmia (heart failure or aggravate existing heart failure)

2. Prolonged tachycardia or any type may lead to (tachycardia induced cardiomyopathy)

Page 18: Pharmacotherapy of Arrhythmias

Diagnosis

1. DETAILED HISTORY SHOULD BE OBTAINED2. HISTORY OF CARDIAC DISEASE3. OTHER DIAGNOSED MEDICAL CONDITION 4. A FULL DRUG HISTORY (Both OTC/Rx)5. A FAMILY HISTORY OF HEART FAILURE 6. A FAMILY HISTORY OF SUDDEN DEATH

Page 19: Pharmacotherapy of Arrhythmias

Mandatory investigation includes

1.12-LEAD ECG2. ECHOCARDIOGRAM3.AMBULATORY ECG (recording for up to 7days)4. Infrequent symptoms an event recorder, ECG strips, Insertable loop recorder

Page 20: Pharmacotherapy of Arrhythmias

Management

• Pathological tachycardia is conventionally defined as resting heart rate over 100/min• Classified as two types

1. SVT (?)2. VT(?)

Page 21: Pharmacotherapy of Arrhythmias

SVTINAPPROPRIATE SINUS TACHYCARDIA

12 LEAD ECG, AMBULATORY ECG, ECHO CARDIOGRAPHY

Beta blockers, verapamil, ivaradine

ATRIAL FLUTTER Right atrial tachycardia with re entry ( 300/min) 1:2 ratio av conduction

Beta blocker, verapamil, diltiazem and digoxin,1:1- sotalol, amiodarone

FOCAL ATRIAL TACHYCARDIA Uncommon arrhythmia discharge of focal source within the atria and surrounding venous structures

Adenosine, class ic, 1:1 av conduction,

JUNCTIONAL RE ENTRY TACHYCARDIA

SVT Used to explain JRTTWO TYPEAVNRTAVRT

Intravenous adenosine 12 mgIntravenous verapamil 5 mgProphylactic drugs: Beta blockers, verapamil, flecainide and sotalol

Page 22: Pharmacotherapy of Arrhythmias
Page 23: Pharmacotherapy of Arrhythmias

Atrial fibrillation :• Most common sustained arrhythmia• Classified as:

1. Paroxysmal – episodes of AF lasting no more than 7days2. Persistent- more than 7days3. Longstanding persistant – more than 7 year4. Permanent- no decision has been made not to attempt cure of persistant AF

Therapy5. ANTICOAGULANT THERAPY6. INTRAVENOUS Beta blockers, verapamil and digoxin7. Several class I (sotalol and amiodarone)8. Class Ic flecainide and class III amiodarone

Page 24: Pharmacotherapy of Arrhythmias
Page 25: Pharmacotherapy of Arrhythmias